Skip to main content
. Author manuscript; available in PMC: 2010 Jan 1.
Published in final edited form as: Radiat Res. 2009 Jan;171(1):9–21. doi: 10.1667/RR1472.1

FIG. 5.

FIG. 5

Radiosensitization of HER2-overexpressing cells by NF-κB inhibition. Panels A and B: Inhibition of HER2 overexpression by IMD-0354 (2 µM for 5 h) in MCF+IR and radioresistant (C4, C5) cells but not in MCF-7/HER2 cells and relatively radiosensitive (C2) MDA+IR cells. Panels C–E: Clonogenic survival of cells of MDA+IR cell lines C2 (panel C), C4 (panel D), and C5 (panel E) pretreated with the NF-κB inhibitor IMD-0354 (2 µM, 5 h) or DMSO before radiation exposure (n = 3; mean ± SE; **P < 0.01 compared to DMSO-treated cells). Panel F: Inhibition of HER2 expression in cells of the radioresistant MDA+FIR cell lines C2 and C4 by NF-κB p65 siRNA. Panels G and H: Clonogenic survival of cells of the radioresistant MDA+FIR cell lines C2 (panel G) and C4 (panel H) treated with NF-κB p65 siRNA (20 nM for 60 h before irradiation; n = 3; mean ± SE; **P < 0.01).